Targeting dihydroorotate dehydrogenase in acute myeloid leukemia.
作者信息
Zeng Zhihong, Konopleva Marina
机构信息
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
出版信息
Haematologica. 2018 Sep;103(9):1415-1417. doi: 10.3324/haematol.2018.197806.
Abstract
摘要
相似文献
1
Targeting dihydroorotate dehydrogenase in acute myeloid leukemia.靶向急性髓系白血病中的二氢乳清酸脱氢酶
Haematologica. 2018 Sep;103(9):1415-1417. doi: 10.3324/haematol.2018.197806.
2
Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells.二氢乳清酸脱氢酶的药理学抑制诱导急性髓系白血病细胞凋亡和分化。
Haematologica. 2018 Sep;103(9):1472-1483. doi: 10.3324/haematol.2018.188185. Epub 2018 Jun 7.
3
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.ASLAN003，一种强效的二氢乳清酸脱氢酶抑制剂，可用于急性髓系白血病的分化治疗。
Haematologica. 2020 Sep 1;105(9):2286-2297. doi: 10.3324/haematol.2019.230482.
4
Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation.二氢乳清酸脱氢酶部分抑制与白血病终末分化之谜。
Haematologica. 2020 Sep 1;105(9):2191-2193. doi: 10.3324/haematol.2020.254482.
5
The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia.二氢乳清酸脱氢酶（DHODH）作为急性髓系白血病治疗靶点的出现。
Expert Opin Ther Targets. 2018 Nov;22(11):893-898. doi: 10.1080/14728222.2018.1536748. Epub 2018 Oct 17.
6
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-]pyridine Scaffold: SAR of the Aryloxyaryl Moiety.基于 2-羟基吡唑并[1,5-a]嘧啶骨架的高效人二氢乳清酸脱氢酶抑制剂靶向治疗急性髓性白血病：芳氧基芳基部分的 SAR。
J Med Chem. 2022 Oct 13;65(19):12701-12724. doi: 10.1021/acs.jmedchem.2c00496. Epub 2022 Sep 26.
7
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors.靶向髓系分化的强效 2-羟基吡唑并[1,5-a]吡啶骨架基于人二氢乳清酸脱氢酶抑制剂。
J Med Chem. 2018 Jul 26;61(14):6034-6055. doi: 10.1021/acs.jmedchem.8b00373. Epub 2018 Jul 9.
8
A new target for differentiation therapy in AML.AML 分化治疗的新靶点。
Cell Res. 2017 Jan;27(1):9-10. doi: 10.1038/cr.2016.130. Epub 2016 Nov 11.
9
Rat dihydroorotate dehydrogenase: isolation of the recombinant enzyme from mitochondria of insect cells.大鼠二氢乳清酸脱氢酶：从昆虫细胞线粒体中分离重组酶
Protein Expr Purif. 1997 Jun;10(1):89-99. doi: 10.1006/prep.1996.0714.
10
Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.布喹那钠对二氢乳清酸脱氢酶活性的抑制作用。
Cancer Res. 1992 Jul 1;52(13):3521-7.
引用本文的文献
1
A Combined Chemical, Computational, and In Vitro Approach Identifies SBL-105 as Novel DHODH Inhibitor in Acute Myeloid Leukemia Cells.一种联合化学、计算和体外方法鉴定 SBL-105 为急性髓系白血病细胞中新型 DHODH 抑制剂。
Oncol Res. 2022 Jan 31;28(9):899-911. doi: 10.3727/096504021X16281573507558. Epub 2021 Aug 5.
本文引用的文献
1
Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells.二氢乳清酸脱氢酶的药理学抑制诱导急性髓系白血病细胞凋亡和分化。
Haematologica. 2018 Sep;103(9):1472-1483. doi: 10.3324/haematol.2018.188185. Epub 2018 Jun 7.
2
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.ivosidenib 治疗 IDH1 突变复发性或难治性 AML 的持久缓解。
N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.
3
Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers.依赖嘧啶生物合成酶 DHODH 是驱动突变 KRAS 癌症的合成致死弱点。
Cell Chem Biol. 2018 Jun 21;25(6):705-717.e11. doi: 10.1016/j.chembiol.2018.03.005. Epub 2018 Apr 5.
4
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.DHODH 抑制剂通过阻断 p53 降解增加 p53 的合成并增强肿瘤细胞杀伤作用。
Nat Commun. 2018 Mar 16;9(1):1107. doi: 10.1038/s41467-018-03441-3.
5
Adaptive Reprogramming of Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer.嘧啶合成的适应性重编程是三阴性乳腺癌的一种代谢弱点。
Cancer Discov. 2017 Apr;7(4):391-399. doi: 10.1158/2159-8290.CD-16-0611. Epub 2017 Mar 2.
6
PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition.PTEN调节谷氨酰胺向嘧啶合成的通量以及对二氢乳清酸脱氢酶抑制的敏感性。
Cancer Discov. 2017 Apr;7(4):380-390. doi: 10.1158/2159-8290.CD-16-0612. Epub 2017 Mar 2.
7
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.XPO1 依赖的核输出是 KRAS 突变型肺癌中的一个可药物靶向的弱点。
Nature. 2016 Oct 6;538(7623):114-117. doi: 10.1038/nature19771. Epub 2016 Sep 28.
8
Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.抑制二氢乳清酸脱氢酶可克服急性髓系白血病中的分化阻滞。
Cell. 2016 Sep 22;167(1):171-186.e15. doi: 10.1016/j.cell.2016.08.057. Epub 2016 Sep 15.
9
Genomic Classification and Prognosis in Acute Myeloid Leukemia.急性髓系白血病的基因组分类与预后
N Engl J Med. 2016 Jun 9;374(23):2209-2221. doi: 10.1056/NEJMoa1516192.
10
Acute Myeloid Leukemia: A Concise Review.急性髓系白血病：简要综述
J Clin Med. 2016 Mar 5;5(3):33. doi: 10.3390/jcm5030033.
Zotero 插件